**NASH-related Publications**

[Meena Bansal](https://www.mountsinai.org/profiles/meena-b-bansal)

**Bansal MB.** Invited Review. Anti-Fibrotics in Liver Disease: Has the time come for routine use? Hepatol Int. 2019 Jan;13(1):25-392018. PMID: 30302735

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, **Bansal MB**, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE.

Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.PMID: 31727409

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Lancet 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5.

[Andrea Branch](https://icahn.mssm.edu/profiles/andrea-d-branch)

Vandromme M, Jun T, Perumalswami P, Dudley JT, Branch A, Li L. Automated phenotyping of patients with non-alcoholic fatty liver disease reveals clinically relevant disease subtypes. Pac Symp Biocomput. 2020;25:91-102. PMID: 31797589; PMCID: PMC7043281.

Jirapatnakul A, Reeves AP, Lewis S, Chen X, Ma T, Yip R, Chin X, Liu S, Perumalswami PV, Yankelevitz DF, Crane M, Branch AD, Henschke CI. Automated measurement of liver attenuation to identify moderate-to-severe hepatic steatosis from chest CT scans. Eur J Radiol. 2020 Jan;122:108723. doi: 10.1016/j.ejrad.2019.108723. Epub 2019 Oct 25. PMID: 31778964; PMCID: PMC7179816.

Chen X, Ma T, Yip R, Perumalswami PV, Branch AD, Lewis S, Crane M, Yankelevitz DF, Henschke CI. Elevated prevalence of moderate-to-severe hepatic steatosis in World Trade Center General Responder Cohort in a program of CT lung screening. Clin Imaging. 2020 Apr;60(2):237-243. doi: 10.1016/j.clinimag.2019.12.009. Epub 2019 Dec 12. PMID: 31945662; PMCID: PMC7191946.

Jirapatnakul A, Yip R, Branch AD, Lewis S, Crane M, Yankelevitz DF, Henschke CI. Dose-response relationship between World Trade Center dust exposure and hepatic steatosis. Am J Ind Med. 2021 Jul 30. doi: 10.1002/ajim.23269. Epub ahead of print. PMID: 34328231.

Chen X, Li K, Yip R, Perumalswami P, Branch AD, Lewis S, Del Bello D, Becker BJ, Yankelevitz DF, Henschke CI. Hepatic steatosis in participants in a program of low-dose CT screening for lung cancer. Eur J Radiol. 2017 Sep;94:174-179. doi: 10.1016/j.ejrad.2017.06.024. Epub 2017 Jun 27. PMID: 28712697.

[Bishaung Cai](https://icahn.mssm.edu/profiles/bishuang-cai)

Cai B, Dongiovanni P, Corey KE, Wang X, Shmarakov IO, Zheng Z, Kasikara C, Davra V, Meroni M, Chung RT, Rothlin CV, Schwabe RF, Blaner WS, Birge RB, Valenti L, Tabas I. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab. 2020 Feb 4;31(2):406-421.e7. doi: 10.1016/j.cmet.2019.11.013. Epub 2019 Dec 12. PMID: 31839486; PMCID: PMC7004886.

Wang X, Cai B, Yang X, Sonubi OO, Zheng Z, Ramakrishnan R, Shi H, Valenti L, Pajvani UB, Sandhu J, Infante RE, Radhakrishnan A, Covey DF, Guan KL, Buck J, Levin LR, Tontonoz P, Schwabe RF, Tabas I. Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. Cell Metab. 2020 May 5;31(5):969-986.e7. doi: 10.1016/j.cmet.2020.03.010. Epub 2020 Apr 6. PMID: 32259482; PMCID: PMC7313619.

Wang X, Sommerfeld MR, Jahn-Hofmann K, Cai B, Filliol A, Remotti HE, Schwabe RF, Kannt A, Tabas I. A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice. Hepatol Commun. 2019 Jul 23;3(9):1221-1234. doi: 10.1002/hep4.1405. Erratum in: Hepatol Commun. 2019 Nov 26;4(1):134. PMID: 31497743; PMCID: PMC6719739.

Cai B, Wang X. Liver cholesterol matters. Aging (Albany NY). 2020 Oct 26;12(20):19828-19829. doi: 10.18632/aging.104208. Epub 2020 Oct 26. PMID: 33125343; PMCID: PMC7655184.

Wang X, Cai B. MerTK, a risk factor for NASH fibrosis. Aging (Albany NY). 2020 Oct 27;12(20):19832-19833. doi: 10.18632/aging.104210. Epub 2020 Oct 27. PMID: 33125345; PMCID: PMC7655196.

[Amreen Dinani](https://www.mountsinai.org/profiles/amreen-dinani2)

**Dinani A**, Khan A, Dieterich D. Emerging Prevalence of Fatty Liver Disease in HIV. Future Viirology. 2021 Jan. https://doi.org/10.2217/fvl-2020-0184

Wu Y, Chuang P, Pinotti R, Nagirimadugu A, Valentin N, **Dinani A**. The Association of Impaired Lung Function and Nonalcoholic Fatty Liver Disease: A Systematic Review.  Eur J Gastroenterol Hepatol.  2021 May 1;33(5):745-751

**Dinani A**, Kowdley K, Noureddin M.Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH- the State of the Art. Hepatology. 2021 Apr 30 https://doi.org/10.1002/hep.31869

[Scott Friedman](https://icahn.mssm.edu/profiles/scott-l-friedman)

## *Peer-reviewed Original Publications*

## Segal-Salto M, Barashi N, Katav A, Edelshtein V, Aharon A, Hashmueli S, George J, Maor Y, Pinzani M, Haberman D, Hall A, Friedman S, Mor A. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Reports, 2(1):100064, 2020.

Sydor S, Best J, Messerschmidt I, Manka P, Vichez-Vargas R, Brodesser S, Lucas C, Annemarie Wegehaupt A, Wenning C, Aßmuth S, Simon Hohenester S, Alexander Link A, Faber KN, Moshage H, Cubero FJ, Friedman SL, Gerken G, Trauner M, Canbay, Bechmann LP. Altered microbiota diversity and bile acid signaling 1 in cirrhotic and non-cirrhotic NASH-HCC. **Clinical and Translational Gastroenterology**, Mar;11(3):e00131, 2020.

Stokman G, van den Hoek AM, Thorbekk DD, Pieterman EJ, Skovgård Veidal S, Basta B, Iruarrizaga-Lejarreta M, José W. van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjæret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. **Liver International,** 40(11):2860-2876, 2020.

Carter JK, Bhattacharya D, Borgerding JN, Fiel MI, Faith JJ, Friedman SL. Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. **PLoS One,** 16(1): e0244763, 2021.

Bhattacharya D, Basta B, Mato, JM Craig A, Fernández-Ramos D, Lopitz-Otsoa F, Tsvirkun D, Hayardeny L, Chandar V, Schwartz RE, Villanueva A and Friedman SL. Aramchol downregulates stearoyl CoA-Desaturase 1 (SCD 1) in hepatic stellate cells to attenuate cellular fibrogenesis. **J** **HEP Reports,** in press**,** 2021.

Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Moeini A, Peix J, Oliveira CP, Alves VA, Boffeta P, Lachenmayer A, Roessler S, Minguez M, Schirmacher P, Dufour J-F, Thung S, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwälder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. **J Hepatology**, in press, 2021.

Nielsen M , Leeming DJ , Goodman Z , Friedman SL , Frederiksen P , Rasmussen DK, Vig P, Seyedkazemi S, Fischer L, Torstenson R, Karsdal MA, Lefebvre E, Sanyal A, Ratziu V. Comparison of ADAPT, FIB4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR Screening Population, **J Hepatology**, in press, 2021.

Torrens L, Montironi C, Puigvehí M, Mesropian A Leslie J. Haber PK, Miho Maeda M, Balaseviciute U, Willoughby CE, Abril-Fornaguera J, Piqué-Gili M, Torres-Martín M, Peix J, Geh D, Ramon-Gil E, Saberi B, Friedman SL, Mann D, Sia D, Llovet JM. Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma. **Hepatology**, in press, 2021.

Manka P, Sydor S, Waze N, Best J, Brandenburg M, Hellbeck A, Schänzer J, Vilchez-Vargas R, Link A, Figge A, Jähnert A, Von Arnim U, Coombes JD, Cubero FJ, Karaman A, Kim MS, Kälsch J, Kinner S, Faber KN, Moshage H, Gerken G,Syn WK, Friedman SL, Canbay A, Bechmann LP. Anti-TNFα treatment in Crohn’s disease: Impact on hepatic steatosis, gut-derived hormones, and metabolic status. **Liver International**, 2021, in press.

Bhattacharya D, Becker C, Readhead B, Goossens N, Novik J, Fiel MI, Cousens LP, Magnusson B, Backmark A, Hicks R, Dudley JT and Friedman SL. Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis. Submitted, 2021.

**Review Articles:**

Young S, Tariq R, Provenza J, Satapathy, SK, Faisal K, Choudhury A, Friedman SL, Singal AK. Prevalence and profile of fatty liver disease in lean adults: a systematic review and meta-analysis. **Hepatology Communications**, 4 (7):953 - 972, 2020.

Asgharpour A,Dinani A,Friedman SL. Basic science to clinical trials in NAFLD & ALD: collaboration with industry. **Translational Gastroenterology and Hepatology**, 6:5, 2021.

Trivedi P, Wang S and Friedman SL. The power of plasticity – metabolic regulation of hepatic stellate cells. **Cell Metabolism**, S1550-4131(20)30595-7, 2021.

Huisman TM, Dieterich DT, Friedman SL. Experimental and investigational targeted therapies for the management of fibrosis in NASH: an update. **J Experimental Pharmacology**, in press, 2021.

Shulman G\*, Friedman SL\*, Loomba R\*. Mechanisms and disease consequences of nonalcoholic fatty liver disease, **Cell,** 184(10):2537-2564, 2021. (\* shared equal authorship).

[Tatyana Kushner](https://www.mountsinai.org/profiles/tatyana-kushner)
Hershman M, Mei R, Kushner T. Implications of Nonalcoholic Fatty Liver Disease on Pregnancy and Maternal and Child Outcomes. Gastroenterol Hepatol (N Y). 2019 Apr;15(4):221-228. PMID: 31435201; PMCID: PMC6696596.

Kushner T, Cafardi J. Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis. Clin Liver Dis (Hoboken). 2020 May 21;15(5):195-199. doi: 10.1002/cld.974. PMID: 32537135; PMCID: PMC7280613.

[Thomas Schiano](https://www.mountsinai.org/profiles/thomas-d-schiano)

Qin J, Higashi T, Nakagawa S, Fujiwara N, Yamashita YI, Beppu T, Baba H, Kobayashi M, Kumada H, Gunasekaran G, Schiano TD, Thung SN, Fiel MI, Hoshida Y, Ward SC. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights. Am J Surg Pathol. 2020 Oct;44(10):1406-1412. doi: 10.1097/PAS.0000000000001533. PMID: 32618599; PMCID: PMC7942811.

Chayanupatkul M, Dasani DB, Sogaard K, Schiano TD. The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter. Transplant Proc. 2021 Jan-Feb;53(1):159-165. doi: 10.1016/j.transproceed.2020.02.160. Epub 2020 May 17. PMID: 32434740.

Winters AC, Mittal R, Schiano TD. A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient. Clin Transplant. 2019 Oct;33(10):e13700. doi: 10.1111/ctr.13700. Epub 2019 Sep 8. PMID: 31441967.